{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-069142","form_type":"8-K","ticker":"ADIL","cik":"0001513525","company_name":"ADIAL PHARMACEUTICALS, INC.","filed_at":"2023-08-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.156470+00:00","generated_at":"2026-06-11T06:08:32.314859+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Adial Pharmaceuticals Q2 net income $1.1M; plans two Phase 3 trials for AD04","bullets":["Net income of $1.1M vs net loss of $3.8M in Q2 2022; includes $2.66M gain from Purnovate sale.","Cash and equivalents $1.2M at June 30, 2023, down from $4.0M at Dec 31, 2022; runway into Q1 2024.","Sale of Purnovate subsidiary reduces cash burn; Adial received $450K upfront, up to $83M in milestones plus 19.9% equity stake in Adovate.","FDA confirmed primary endpoint (Percentage No Heavy Drinking Days) for AD04; planning two parallel Phase 3 trials.","R&D expense down 37%, G&A down 59% YoY due to lower trial activities and cost reductions."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-069142","json":"https://secwatch.observer/filing/0001213900-23-069142.json","markdown":"https://secwatch.observer/filing/0001213900-23-069142.md","text":"https://secwatch.observer/filing/0001213900-23-069142.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1513525/000121390023069142/0001213900-23-069142-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1513525/000121390023069142/ea183948-8k_adialpharm.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T06:08:32.314859+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0b82b9f61e915da8448e90fe69c311973f5db27d","claim":"ADIAL PHARMACEUTICALS, INC. reported second quarter of 2023 results: net income $1.1 million.","evidence_excerpt":"Adial Pharmaceuticals Reports Second Quarter 2023 Financial Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390023069142/0001213900-23-069142-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter of 2023"},{"label":"Net income","value":"$1.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}